TAG ARCHIVES FOR human subjects protections

2
Nov2018

My path has been anything but traditional: I came to the world of academia from a long career as a circus and stunt performer and world-record competitive formation skydiver. As a member of the esoteric, misunderstood communities of professional aerial acrobats, I’ve always felt personally connected to and passionate about fieldwork and research ethics. This month, I am starting a new position at BGSU, as the new Research Compliance Officer of our university. It is a thrilling challenge for me to take on this new level of responsibility and commitment, and it makes this particular PRIM&R meeting exceptionally crucial for me. As I stand on the edge of the transition from professor/board member to official compliance officer, I’m seeking mentors and resources that can help me in my highest dive ever, into a deeper understanding of the world of human subjects research protection. I’m honored to share my reflections on this journey through the PRIM&R Blog Squad! Read more

30
Oct2018

I am thrilled to attend my second PRIM&R Advancing Ethical Research Conference (AER18) and to share my experiences as a Blog Squad member! With so many recent and forthcoming regulatory changes—the revised Common Rule, NIH single IRB of record mandate, and the EU General Data Protection Regulation (GDPR), just to name a few—this is an exciting time for the human research projections community, and I am delighted to explore these topics with you! Read more

21
Aug2018

On May 30, 2018, the four-year Right to Try (RTT) movement culminated in a new federal law, with the stated goal of providing terminally ill patients with a new route of access to early phase investigational drugs that are currently in clinical development and not approved or generally available to all patients in need. RTT laws seek to remove federal FDA oversight and regulations from the pre-approval process, in which patients seek to access experimental drugs in development outside of the clinical trials in which the drugs are being tested, despite the fact that terminally ill patients already had the right to request such access under FDA regulations for decades through the Expanded Access Program. Read more

13
Aug2018

You are the chief human research protections officer at a prestigious academic medical center (AMC). You have just discovered that two doctors on your staff have been secretly conducting a clinical study on their patients. The doctors have broken every rule in the human subjects protection book. They did not even tell their patients they were in a clinical study, and some of them died. The president of the AMC has called a meeting this afternoon where you will have to explain the situation and make your recommendations. What a nightmare! To complicate things, it turns out that the study treatment is an astonishing medical breakthrough that can save thousands of lives. The doctors want to submit a paper to a major medical journal by the end of the week. A Nobel Prize could be in order. Read more

21
May2018

On April 30, 2018, the EPA published in the Federal Register a proposed rule titled, Strengthening Transparency in Regulatory Science. The rule would prohibit the EPA from basing regulatory action on scientific studies for which the underlying raw data and models are not publicly available “in a manner sufficient for validation and analysis.” According to the notice, the proposed rule is “designed to increase transparency in the preparation, identification, and use of science in policymaking.” On its face, this sounds good; however, many in the scientific community are expressing deep concern that this proposed rule is actually a way for EPA to limit the types of science it can and will use in regulatory decision-making, to the detriment of environmental policy and the public’s health. Comments on the proposed rule are due May 30. Read more